

**Iowa Medicaid Pharmaceutical and Therapeutics Committee
Minutes**

Date: April 20, 2023

Chairperson: Mark Graber, M.D.

Erin Halverson, Iowa Medicaid staff, assisted in running the meeting with the Chairperson due to the virtual format.

Time: 9:33 a.m. to 11:31 a.m.

Location: WebEx Teleconference (due to Federal PHE Declaration for the COVID-19 Pandemic)

Due to the current federal state of emergency, continually fluctuating numbers of coronavirus cases in various counties, the need for stability and pre-planning for the public, and due to increased workload of our members directly related to the COVID-19 pandemic, the Committee finds that it is impossible/impractical to meet in person for the April 20, 2023 meeting, and that it must be held electronically.

Committee Members Present: Mark Graber, M.D.; Charles Wadle, D.O.; Abby Cate, Pharm.D.; Jason Kessler, M.D.; Tricia White, R.N.; and Rachel Reinsvold, Pharm.D. (Vacancies July 2021: 1 Physician, 1 Physician Assistant)

Iowa DHS Staff Present: Susan Parker, Pharm.D., Pharmacy Consultant; and Krissa Mason, Assistant Attorney General.

Iowa Medicaid Staff Present: Laureen Biczak, D.O.; Ryan Fell, Pharm.D.; Erin Halverson, R.Ph.; Gina Kuebler, R.Ph.; Pam Smith, R.Ph.; and Melissa Biddle.

Managed Care Organization (MCO) Staff Present: Jeannine Murray, Amerigroup Iowa; Emily Rogers, Iowa Total Care; and Candace Jordan Molina Healthcare of Iowa.

Chairperson Mark Graber called the meeting to order.

- I. Mark Graber asked that each committee and DHS and IME staff member introduce themselves to the public. Abby Cate made the motion to approve the November minutes, and Rachel Reinsvold seconded. The motion passed with no objections. There were no new verbal conflict of interest disclosures.
- II. PDL Revision Notifications (Erin Halverson): The fax blasts sent to providers since the last P&T Meeting in August, to notify them of preferred drug list changes, were reviewed. Due to availability issues for oseltamivir and albuterol products, Tamiflu capsules and oral suspension and ProAir RespiClick will be made preferred on the PDL.
- III. Drug Rebate Issues (Dr. Fell): With regards to recent insulin price reductions from the major manufacturers, there is a provision in the American Rescue Plan Act that removes what is

currently a 100% average manufacturer price cap on these products for the federal rebates. As of today, if an inflationary component or best price provision of a federal rebate were to exceed 100% of the manufacturer's average manufacturing price, that is where it would currently be capped. However, within the American Rescue Plan Act beginning January 1, 2024, that would be removed, and the manufacturer would potentially have to pay a state for utilization of a product exceeding that price at which they are producing it. The insulin manufacturers are a major offender of this inflated pricing, and one of the reasons for the recent price reductions. Additionally, within the Inflation Reduction Act, there are Medicare specific inflation penalties, essentially modeled after the Medicaid drug rebate program, which are also being enacted and will affect these products, as well. It's also likely there will be a future expansion of the Inflation Reduction Act that would apply to commercial plans not currently affected, capping insulin products at \$35.

- IV. PA Criteria/Pro-DUR Edits (Dr. Parker): Susan Parker reviewed the informational letters that had been sent out since the last P&T Meeting in August, all posted online at http://iowamedicaidpdl.com/informational_letters and http://iowamedicaidpos.com/latest_news. Providers received Informational Letters 2405-MC-FFS and 2428-MC-FFS related to PDL and prior authorization criteria changes that went into effect January 1, 2023, and April 1, 2023, respectively, following the November P&T and DUR Meetings and the February DUR Meeting. Informational Letter 2426-MC-FFS-CVD notified providers about the end of COVID-19 Public Health Emergency (PHE) pharmacy allowances, effective May 12, 2023. The committee also received copies of the letter sent to the Department of Health and Human Services from the DUR Commission after their February meeting, which included recommendations for quantity limits and ProDUR age limits for select drugs, removal of prior authorization criteria for Nebivolol (Bystolic) and Potassium Binders, and new and updated prior authorization criteria recommendations for: Select Topical Psoriasis Agents, Initial Days' Supply Limit Override for Benzodiazepines, and High Dose Opioids
- V. Legislation (Dr. Parker): There were no updates.
- VI. IME Updates (Dr. Parker): There was nothing new to report.
- VII. Public Comment: As this meeting was purely virtual, only written public comment was accepted. The committee members reviewed the received comments, which are posted at: <http://www.iowamedicaidpdl.com/public-comments>. They were also forwarded manufacturer comments as they were received via email prior to the meeting.

Provider Comments Received:
Imcivree

Manufacturer Comments Received:
Ztalmy, Xelstrym, Pheburane, Briviact, Nayzilam, Vraylar, Hyftor, Sunlenca, Auvelity, Imcivree, Sotyktu

Dr. Kessler inquired about coverage of Imcivree. It was noted that it currently isn't covered as Iowa's current state plan reflects Iowa Medicaid does not cover drugs for weight loss. A change to this policy would require a state plan amendment and approved funding. It could, however, be

considered under exception to policy (ETP). He requested information regarding how many ETPs have been submitted with outcome.

At 9:46, Abby Cate motioned to go to closed session as authorized by Iowa Code Section 21.5(1)(a) of the Open Meetings Law to review or discuss economic records associated with the PDL which are required or authorized to be kept confidential. Jason Kessler seconded, and the motion passed with unanimous roll call approval. Open session resumed at 10:23.

VIII. PDL Discussion and Deliberation (Erin Halverson): All subsequent recommendations (with numbering as provided on agenda attachment 2) were made to maximize cost savings to the program unless otherwise noted.

1. Vilazodone to Preferred.
2. Trimipramine to Non-Preferred (grandfather existing users).
3. Methoxsalen Capsules to Non-Preferred.
4. Insulin glargine Pen and Vial to Preferred, labeler 00955 only. Lantus remains Preferred.
5. Ziextenzo to Non-Preferred with Conditions.

Chuck Wadle motioned to accept the recommendations above, and Abby Cate seconded. The decision was unanimous.

The drugs listed below were recommended to be removed from coverage under the pharmacy benefit, as they are intended to be administered in a healthcare/office setting (coverage and billing is available through the medical benefit):

1. Fabrazyme Injection
2. Carnitor Injection
3. Chlorothiazide Sodium Injection
4. Calcitriol Injection
5. Naglazyme Injection
6. Aldurazyme Injection
7. Regonol Injection
8. Nitroglycerin in D5W Injection
9. Caldolor Injection
10. Levothyroxine Sodium for IV Injection
11. Triostat (liothyronine) IV solution

Abby Cate motioned to accept the recommendations above, and Chuck Wadle seconded. The decision was unanimous.

IX. RDL Discussion and Deliberation (Erin Halverson): The drugs listed below were recommended to be removed from coverage under the pharmacy benefit, as they are intended to be administered in a healthcare/office setting (coverage and billing is available through the medical benefit):

1. Cyclophosphamide IV Solution
2. Melphalan Injection

Abby Cate motioned to accept the recommendations above, and Jason Kessler seconded. The decision was unanimous.

X. Newly Released Drugs (Dr. Biczak): All following recommendations (with numbering as provided on agenda attachment 4) were made to maximize cost savings to the program unless otherwise noted. Complete new drug monographs can be found on the November meeting page at http://iowamedicaidpdl.com/schedule_page/april-20-2023. Dr. Biczak reviewed the new drugs, and the recommendations were as follows:

1. Auvelity- Recommend status on the PDL as Non-Preferred with Conditions
2. Hyftor Gel- Recommend status on the PDL as Non-Preferred
3. Lytgobi- Recommend status on the RDL as Non-Recommended with Conditions
4. Rezlidhia- Recommend status on the RDL as Non-Recommended with Conditions
5. Rolvedon- Recommend status on the PDL as Non-Preferred with Conditions
6. Sotyktu- Recommend status on the PDL as Non-Preferred with Conditions
7. Sunlenca tablets- Recommend status on the RDL as Non-Recommended
8. Verkazia- Recommend status on the PDL as Non-Preferred
9. Vivjoa- Recommend status on the PDL as Non-Preferred with Conditions
10. Ztalmly- Recommend status on the PDL as Non-Preferred

Abby Cate motioned to accept the recommendations above as amended, and Rachel Reinsvold seconded. The decision was unanimous.

XI. Newly Released Generic Drugs (Erin Halverson): All following recommendations were made to maximize cost savings to the program unless otherwise noted.

Drug Name	PDL/RDL Recommendation
Clonidine ER Tab	Non-Preferred
Diclofenac Oral Packet	Non-Preferred with Conditions
Estradiol Gel	Non-Preferred
Fingolimod	Non-Preferred with Conditions
Insulin Degludec Pen Injector	Non-Preferred
Insulin Degludec Vial	Non-Preferred
Lurasidone	Preferred Step 1
Methylphenidate Osmotic Release Tabs 45mg & 63mg	Non-Preferred with Conditions
PEG 3350-Kcl-NaCl-Na Sulf-Na Ascorbate-C for Solution	Non-Preferred
Penciclovir Cream	Non-Preferred
Roflumilast	Preferred with Conditions
Sodium Oxybate Oral Solution	Non-Preferred with Conditions
Tafluprost	Non-Preferred
Tasimelteon	Non-Preferred with Conditions

Chuck Wadle motioned to accept the recommendations above. Abby Cate seconded, and all members were in favor.

- XII. New Drug Dosage Forms/Strengths/Combinations/BioSimilar (Erin Halverson): All following recommendations were made to maximize cost savings to the program unless otherwise noted.

Drug Name	PDL/RDL Recommendation
Adapalene / Benzoyl Peroxide Pad 0.1-2.5%	Non-Preferred with Conditions
Entadfi	Non-Preferred
Ermeza Oral Solution	Non-Preferred
Fylnetra	Preferred with Conditions
Humalog Tempo	Non-Preferred
Lyumjev Tempo	Non-Preferred
Pheburane Oral Pellet	Non-Preferred
Relexxii	Non-Preferred with Conditions
Ryaltris	Non-Preferred
Stimufend	Non-Preferred with Conditions
Tadliq Oral Suspension	Non-Preferred with Conditions
Xaciato 2% Vaginal Gel	Non-Preferred
Xelstrym	Non-Preferred with Conditions

Jason Kessler motioned to accept the recommendations above. Rachel Reinsvold seconded, and all members were in favor.

- XIII. Biosimilar Drugs Presentation (Dr. Biczak and Dr. Fell): A PowerPoint outlining approval pathways, indications and “skinny labels”, implications of “method of use” codes, and market trends and uptake was presented.

A motion was made by Abby Cate to adjourn the meeting. It was seconded by Rachel Reinsvold, and all in attendance approved. The meeting adjourned at 11:31 a.m. The next scheduled meeting is tentatively set for August 17, 2023.